Drug liking

Last updated

Drug liking is a measure of the pleasurable (hedonic) experience when a person consumes drugs. [1] It is commonly used to study the misuse liability of drugs. [2] [3] [4] Drug liking is often measured using unipolar and bipolar visual analogue scales (VAS), such as the Drug Liking VAS, the High VAS, the Take Drug Again (TDA) VAS, and the Overall Drug Liking (ODL) VAS. [2] [4] There is a dissociation of drug liking from drug wanting (unconscious attribution of incentive salience). [1] [5] Drugs that increase scores on drug-liking measures include amphetamines, cocaine, methylphenidate, MDMA, opioids, benzodiazepines, Z-drugs, barbiturates, alcohol, nicotine, and caffeine (limitedly), among others. [3] [6] [4] [7] [8] [9] [10] [11] [12]

References

  1. 1 2 Tibboel H, De Houwer J, Van Bockstaele B (October 2015). "Implicit measures of "wanting" and "liking" in humans". Neurosci Biobehav Rev. 57: 350–64. doi:10.1016/j.neubiorev.2015.09.015. hdl: 1854/LU-6956559 . PMID   26432503. S2CID   16243037.
  2. 1 2 Sellers EM (April 2018). "Improving the Clinical Pharmacologic Assessment of Abuse Potential: Part 2: Optimizing the Design of Human Abuse Potential Studies". J Clin Psychopharmacol. 38 (2): 113–118. doi:10.1097/JCP.0000000000000838. PMID   29360651. S2CID   3506269.
  3. 1 2 Foltin RW, Fischman MW (June 1991). "Assessment of abuse liability of stimulant drugs in humans: a methodological survey". Drug Alcohol Depend. 28 (1): 3–48. doi:10.1016/0376-8716(91)90052-z. PMID   1679387.
  4. 1 2 3 Comer SD, Zacny JP, Dworkin RH, Turk DC, Bigelow GE, Foltin RW, Jasinski DR, Sellers EM, Adams EH, Balster R, Burke LB, Cerny I, Colucci RD, Cone E, Cowan P, Farrar JT, Haddox DJ, Haythornthwaite JA, Hertz S, Jay GW, Johanson CE, Junor R, Katz NP, Klein M, Kopecky EA, Leiderman DB, McDermott MP, O'Brien C, O'Connor AB, Palmer PP, Raja SN, Rappaport BA, Rauschkolb C, Rowbotham MC, Sampaio C, Setnik B, Sokolowska M, Stauffer JW, Walsh SL (December 2012). "Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations". Pain. 153 (12): 2315–2324. doi:10.1016/j.pain.2012.07.035. PMC   3494795 . PMID   22998781.
  5. ↑ Robinson TE, Berridge KC (1993). "The neural basis of drug craving: an incentive-sensitization theory of addiction". Brain Res Brain Res Rev. 18 (3): 247–91. doi:10.1016/0165-0173(93)90013-p. hdl: 2027.42/30601 . PMID   8401595. S2CID   13471436.
  6. ↑ Ermer JC, Pennick M, Frick G (May 2016). "Lisdexamfetamine Dimesylate: Prodrug Delivery, Amphetamine Exposure and Duration of Efficacy". Clin Drug Investig. 36 (5): 341–56. doi:10.1007/s40261-015-0354-y. PMC   4823324 . PMID   27021968.
  7. ↑ Volkow ND, Swanson JM (November 2003). "Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD". Am J Psychiatry. 160 (11): 1909–18. doi:10.1176/appi.ajp.160.11.1909. PMID   14594733.
  8. ↑ Baylen CA, Rosenberg H (July 2006). "A review of the acute subjective effects of MDMA/ecstasy". Addiction. 101 (7): 933–47. doi:10.1111/j.1360-0443.2006.01423.x. PMID   16771886.
  9. ↑ Griffiths RR, Roache JD (1985). "Abuse Liability of Benzodiazepines:A Review of Human Studies Evaluating Subjective and/or Reinforcing Effects". The Benzodiazepines: Current Standards for Medical Practice. Springer Netherlands. pp. 209–225. doi:10.1007/978-94-009-4886-0_16. ISBN   978-94-010-8663-9.
  10. ↑ Kuhn CM, Koob GF, Heinz A, Beck A, Mir J, Grüsser SM, Grace AA, Wrase J (2010). Alcohol Craving and Relapse Prediction: Imaging Studies. Frontiers in Neuroscience. CRC Press. ISBN   978-0-8493-7391-6. PMID   21656973.
  11. ↑ Kalman D, Smith SS (June 2005). "Does nicotine do what we think it does? A meta-analytic review of the subjective effects of nicotine in nasal spray and intravenous studies with smokers and nonsmokers". Nicotine Tob Res. 7 (3): 317–33. doi:10.1080/14622200500125385. PMID   16085500.
  12. ↑ Griffiths RR, Woodson PP (February 1988). "Reinforcing properties of caffeine: studies in humans and laboratory animals". Pharmacol Biochem Behav. 29 (2): 419–27. doi:10.1016/0091-3057(88)90180-3. PMID   3283780. S2CID   25399469.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.